Cargando…

Cyanorona-20: The first potent anti-SARS-CoV-2 agent

Explicit hindrance and blockade of the viral RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 is considered one of the most promising and efficient approaches for developing highly potent remedies for COVID-19. However, almost all of the reported viral RdRp inhibitors (either repurposed or new anti...

Descripción completa

Detalles Bibliográficos
Autor principal:	Rabie, Amgad M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164343/ https://www.ncbi.nlm.nih.gov/pubmed/34247016 http://dx.doi.org/10.1016/j.intimp.2021.107831

Ejemplares similares

RETRACTED ARTICLE: Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug
por: Rabie, Amgad M.
Publicado: (2021)

Retraction Note to: Discovery of (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug
por: Rabie, Amgad M.
Publicado: (2022)

Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012/01 strain
por: Rabie, Amgad M.
Publicado: (2021)

Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles
por: Rabie, Amgad M.
Publicado: (2021)

Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication
por: Rabie, Amgad M.
Publicado: (2022)

Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro
por: Svenningsen, Esben B., et al.
Publicado: (2021)

Promising Experimental Anti-SARS-CoV-2 Agent “SLL-0197800”: The Prospective Universal Inhibitory Properties against the Coming Versions of the Coronavirus
por: Rabie, Amgad M., et al.
Publicado: (2023)

Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: In Silico and In Vitro Studies
por: Rabie, Amgad M., et al.
Publicado: (2022)

Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
por: Sekirov, Inna, et al.
Publicado: (2021)

A potent inflammatory response is triggered in asymptomatic blood donors with recent SARS-CoV-2 infection
por: Martins, Marina Lobato, et al.
Publicado: (2022)

The Duration and Determinants of Anti-SARS-CoV-2 Immunoglobulin G in Cancer Patients with SARS-CoV-2 Infection: A Longitudinal Study
por: Jiang, Yao, et al.
Publicado: (2022)

Evaluation of the new 2.0 version of the Roche SARS-CoV-2 Rapid Antigen Test
por: Flinck, Heini, et al.
Publicado: (2023)

Duration of anti-SARS-CoV-2 antibodies much shorter in India
por: Kumar, Nishant, et al.
Publicado: (2021)

Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species
por: Eltayb, Wafa A., et al.
Publicado: (2023)

Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation via machine learning
por: Qin, Zhen, et al.
Publicado: (2021)

Anti SARS-CoV-2 seroprevalence in Zanzibar in 2021 before the Omicron wave
por: Salum, Salum Seif, et al.
Publicado: (2022)

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
por: Liu, Xianglei, et al.
Publicado: (2020)

Potent neutralization of SARS‐CoV‐2 including variants of concern by vaccines presenting the receptor‐binding domain multivalently from nanoscaffolds
por: Halfmann, Peter J., et al.
Publicado: (2021)

Syncope at SARS-CoV-2 onset
por: Canetta, Ciro, et al.
Publicado: (2020)

Phylogenetic and whole genome analysis of first seven SARS-CoV-2 isolates in Bangladesh
por: Sharif, Nadim, et al.
Publicado: (2020)

First case of postmortem study in a patient vaccinated against SARS-CoV-2
por: Hansen, Torsten, et al.
Publicado: (2021)

Standardization of two SARS-CoV-2 serology assays to the WHO 20/136 human standard reference material
por: Freeman, James, et al.
Publicado: (2022)

Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
por: Gressens, Simon B., et al.
Publicado: (2023)

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS
por: de Jong, Karen A.M., et al.
Publicado: (2021)

Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence
por: Gouvea, Maria da Penha Gomes, et al.
Publicado: (2022)

Iota-carrageenan extracted from red algae is a potent inhibitor of SARS‐CoV-2 infection in reconstituted human airway epithelia
por: Bovard, David, et al.
Publicado: (2021)

Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit
por: Krüttgen, Alexander, et al.
Publicado: (2021)

The circulation of Non-SARS-CoV-2 respiratory viruses and coinfections with SARS-CoV-2 during the surge of the Omicron variant
por: Eldesouki, Raghda E., et al.
Publicado: (2022)

Accuracy of Allplex SARS-CoV-2 assay amplification curve analysis for the detection of SARS-CoV-2 variant Alpha
por: Čretnik, Tjaša Ž, et al.
Publicado: (2022)

Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses
por: Joseph, Jeswin, et al.
Publicado: (2021)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

Sensitivity of SARS‐CoV‐2 to different temperatures
por: Lv, Qi, et al.
Publicado: (2020)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Syndromic approach to SARS-CoV-2 detection using QIAstat-Dx SARS-CoV-2 panel from clinical samples
por: Gupta, Akshita, et al.
Publicado: (2021)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells
por: Salaris, Claudio, et al.
Publicado: (2021)

The first Italian outbreak of SARS‐CoV‐2 B.1.1.7 lineage in Corzano, Lombardy
por: Messali, Serena, et al.
Publicado: (2021)

Impact of affluence on the local spread of SARS-CoV2 during the first wave of the COVID-19 pandemic
por: Sturrock, B.R.H., et al.
Publicado: (2021)

Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2
por: Cerutti, Francesco, et al.
Publicado: (2020)

Potential neuroinvasive and neurotrophic properties of SARS-CoV-2 in pediatric patients: comparison of SARS-CoV-2 with non-segmented RNA viruses
por: Chen, Xiaodi
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nvj6a89836ig0v78dra8feikkj